Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cancer Survival Rates will be Boosted by Drug Development

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
Bristol-Myers Squib’s research chief discusses pharmaceutical innovations at UCSF cancer center showcase.

The rate of cancer survival is expected to keep climbing in coming years largely thanks to research discoveries that are translating into new cancer drugs, which currently account for roughly 30 percent of the pharmaceutical dollar, the chief scientific officer at Bristol-Myers Squib recently said at a showcase event for the UCSF Helen Diller Family Comprehensive Cancer Center.

“Improvements in innovation in detection, prevention and treatment have provided real gains against cancers over the past few decades,” Elliott Sigal, MD, PhD, also Bristol-Myers Squib's president of research and development and a former UCSF medical resident, said during his Nov. 7 keynote address at the cancer center.

“Overall, age-adjusted, five-year survival rates in the U.S. have increased by more than one-third since 1975,” Sigal noted. “What’s more, it is estimated that advances in drug therapy - pharmaceuticals - accounted for half or more of these increases in survival rates.”

Sigal discussed three areas of innovation that he said were almost certain to continue to drive cancer survival upward.

The first is an explosion of genetic discoveries that are leading to innovations in drug design and to the better tailoring of treatments to the characteristics of individual tumors, Sigal said.

The second is the development of better chemical strategies for delivering drugs to targeted cancer cells within the body. The third thrust is the pharmaceutical manipulation of the body’s own immune system to more aggressively attack cancerous cells.

The successful translation of research discovery into better outcomes for patients depends on companies, universities and government, according to Sigal.

“We live in an ecosystem of contributions in the biomedical enterprise: small companies, large companies, government funding - and very importantly - academic researchers,” he said. “Without any one piston of the engine firing, things will fail.”

The UCSF Helen Diller Family Comprehensive Cancer Center, which recently received a renewal grant from the National Institutes of Health (NIH), unites top scientists with exceptional medical practitioners.

Their interdisciplinary teamwork enables them not only to make key scientific discoveries, but also to ensure that the knowledge gained leads to better treatments for patients.

UCSF’s long tradition of excellence in cancer research includes, notably, the Nobel Prize-winning work of J. Michael Bishop, MD, UCSF chancellor emeritus, and Harold Varmus, MD, who discovered cancer-causing oncogenes.

Their work opened new doors for exploring genetic mistakes that cause cancer, and formed the basis for some of the most important cancer research happening today.

Cancers Grouped by Genetic Mutations
The discovery of genetic alterations within cells that drive molecular events leading to their out-of-control growth - and to tumor formation, growth and spread - has changed the way medical researchers think of cancers and their treatment.

Cancer researchers have been working with the National Institutes of Health to construct the Cancer Genome Atlas, a catalog of the mutations that are responsible for normal cells becoming cancerous.

This growing understanding of mutations in cancer in turn has led to a better understanding of the chains of biochemical events that make a cell cancerous and to the identification of many new molecular targets for pharmaceutical development, Sigal said. This new knowledge also has been used to identify more effective ways to use already marketed drugs.

“Scientists and physicians are beginning to understand the underlying variability of how patients respond to the same drug treatment,” Sigal said.

Tumors have always been named for the organs in which they originate, but when it comes to drug treatment they now are being thought of more often in terms of genetic mutations and their implications, many of which are shared across organ types, Sigal said.

For example, Sigal said, “Some lung cancers may respond to drug therapy more like a select set of colon cancers, or like some prostate cancers, rather than like other types of lung cancer.” Increasingly, biomarkers and genetic tests are available to identify tumors that will respond best to particular treatments. Now drug companies can test experimental treatments in subsets of patients expected to have the most benefit.

“You could theoretically have a smaller and faster clinical program,” and be less likely to miss recognizing an effective treatment, Sigal said.

Attacking Tumors with Fewer Side Effects
Some immune antibodies that target molecules that often are present on certain types of tumors already have been developed and marketed as cancer drugs, but combining antibodies with existing chemotherapies, which are powerful toxins, is another promising approach.

“We have been working on this for 20 or 30 years or more,” he said. “There have been ups and downs.”

However, new chemical strategies hold promise, he added, especially those that use chemical “linkers” with special properties to attach an antibody to a drug and to release the active drug within a tumor cell.

“You can use the homing mechanism of the antibody to be very, very specific, and the nature of the chemistry to release the cytotoxic agent only when necessary and only when effective,” Sigal said.

Using Immune System to Fight Cancer
It’s been a century since physicians first recognized that tumors occasionally regressed when the immune system was activated as a result of an acute infection.

But only in recent years have scientists uncovered many of the details about how immune responses begin, end and are directed to specific targets. Now they have begun to manipulate these responses.

Normally the immune system accepts a tumor as part of the self, but academic researchers and drug companies have conspired to successfully rev up the immune system to fight cancer.

UCSF researchers and oncologists have played a key role in developing and testing immunotherapies that enhance the body’s own immune response. These treatments include Yervoy, which releases the brakes that hold back the immune system from fighting cancer, and Provenge, which in 2010 became the first vaccine approved to treat any cancer. Provenge was approved for the treatment of prostate cancer, following early studies led by UCSF oncologist Eric Small, MD.

Vervoy was shepherded through the final stages of clinical trials by Bristol-Myers Squibb and now is an approved treatment for melanoma, the most deadly skin cancer.

The pharmaceutical giant bought both of the smaller companies that first developed and combined two different drug strategies to create the new treatment, which is based on scientific discoveries by James Allison, PhD, a former member of the UC Berkeley faculty and of UCSF’s cancer center, who now chairs the University of Texas MD Anderson Cancer Center Department of Immunology.

“We’re used to delivering an agent and watching the tumor shrink, but in this case you incite an inflammatory reaction and the tumor swells,” Sigal said. “Many of our competitors missed this scientific fact and thought it actually was progression of disease.”

Melanomas, however, have completed vanished among a significant fraction of patients treated with Yervoy without returning for five years or more, Sigal said, and for all melanoma patients treated in clinical trials, the likelihood of survival has roughly doubled. “Once the immune system is reactivated the responses to fight tumors can be quite profound and quite durable,” he said.

Sigal wants to better target the drug to patients most likely to benefit, but the company also aims to evaluate Yervoy combined with radiation, or with traditional chemotherapy or with other drugs that activate the immune system. The focus of these clinical trials will be prostate, ovarian and lung cancer, Sigal said.

Universities have been a major source of new drugs, and strong ties between sectors remain crucial to developing better treatments and improving cancer survival, according to Sigal.

“A focus on partnerships to extend our reach and scope has been critical to all R&D [research and development] organizations,” he said. “We’re in a very globally interconnected world. Science is more and more complex. The regulatory environment is very demanding, and we are all resource-constrained. Research grants are very hard to come by. … And we have to share our ideas and resources more than ever. Academia is critical to everything that the industry does.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Tuesday, September 29, 2015
Virus In Cattle Linked To Human Breast Cancer
A new study by UC Berkeley researchers establishes for the first time a link between infection with the bovine leukemia virus and human breast cancer.
Wednesday, September 16, 2015
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Tuesday, July 28, 2015
Engineers Crack DNA Code of Autoimmune Disorders
Researchers have identified an unexpectedly general set of rules that determine which molecules can cause the immune system to become vulnerable to the autoimmune disorders lupus and psoriasis.
Wednesday, June 10, 2015
Using microRNA Fit to a T (Cell)
Researchers show B cells can deliver potentially therapeutic bits of modified RNA.
Friday, November 29, 2013
Autoimmune Disease Strategy Emerges from Immune Cell Discovery
UCSF experiments halt pancreas destruction in mouse model of diabetes.
Wednesday, September 11, 2013
Tuberculosis and Parkinson’s Disease Linked by Unique Protein
UCSF researchers seek way to boost protein to fight both diseases.
Wednesday, September 11, 2013
Therapy Could Treat Breast Cancer that's Spread to Brain
Researchers have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.
Tuesday, August 06, 2013
Immune System Molecule Promotes Tumor Resistance
A team of scientists has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.
Tuesday, August 06, 2013
Intestinal Bacteria May Fuel Inflammation and Worsen HIV Disease
Changes in intestinal bacteria may help explain why successfully treated HIV patients still experience life-shortening chronic diseases.
Friday, July 12, 2013
Prenatal Maternal Antibodies Affect Child Development
Prenatal exposure to specific combinations of antibodies found only in mothers of children with autism leads to changes in the brain that adversely affect behavior and development.
Wednesday, July 10, 2013
Absence of Gene Leads to Earlier, More Severe Case of Multiple Sclerosis
UCSF finding in animal study may lead to biomarker that predicts course of disease in humans.
Tuesday, June 25, 2013
Developmental Protein Plays Role in Spread of Cancer
A protein used by embryo cells during early development, and recently found in many different types of cancer, apparently serves as a switch regulating metastasis.
Tuesday, June 18, 2013
Depression Linked to Telomere Enzyme, Aging, Chronic Disease
The first symptoms of major depression may be behavioral, but the common mental illness is based in biology — and not limited to the brain.
Thursday, May 23, 2013
Program for Breakthrough Biomedical Research to Celebrate 15 Years
A program that fosters basic science projects of potentially high impact is celebrating 15 years of discovery at UC San Francisco.
Tuesday, May 21, 2013
Scientific News
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gene-Edited Immune Cells Treat ‘Incurable’ Leukaemia
A new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells programmed to hunt out and kill drug resistant leukaemia has been used at Great Ormond Street Hospital (GOSH).

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos